[go: up one dir, main page]

BR0318278A - compostos de éter aminocicloexìlico e usos dos mesmo - Google Patents

compostos de éter aminocicloexìlico e usos dos mesmo

Info

Publication number
BR0318278A
BR0318278A BRPI0318278-9A BR0318278A BR0318278A BR 0318278 A BR0318278 A BR 0318278A BR 0318278 A BR0318278 A BR 0318278A BR 0318278 A BR0318278 A BR 0318278A
Authority
BR
Brazil
Prior art keywords
ether compounds
aminocyclohexyl ether
compounds
compositions
present
Prior art date
Application number
BRPI0318278-9A
Other languages
English (en)
Other versions
BRPI0318278B1 (pt
BRPI0318278B8 (pt
Inventor
Gregory N Beatch
Lewis Siu Leung Choi
Grace Jung
Yuzhong Liu
Bertrand Plouvier
Richard Wall
Jeff Zhu
Alexander Zolotoy
Anthony G M Barrett
Doug Ta Hung Chou
Tao Sheng
Michael J A Walker
Sandro L Yong
Original Assignee
Cardiome Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiome Pharma Corp filed Critical Cardiome Pharma Corp
Publication of BR0318278A publication Critical patent/BR0318278A/pt
Publication of BRPI0318278B1 publication Critical patent/BRPI0318278B1/pt
Publication of BRPI0318278B8 publication Critical patent/BRPI0318278B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

"COMPOSTOS DE éTER AMINOCICLOEXìLICO E USOS DOS MESMOS". São divulgados compostos de éter aminocicloexílico. Os compostos da presente invenção podem ser incorporados em composições e kits. A presente invenção também divulga os usos para os compostos e as composições, incluindo o tratamento de arritmia.
BRPI0318278A 2003-05-02 2003-10-31 Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro BRPI0318278B8 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US46715903P 2003-05-02 2003-05-02
US47608303P 2003-06-04 2003-06-04
US47644703P 2003-06-05 2003-06-05
US47591203P 2003-06-05 2003-06-05
US47588403P 2003-06-05 2003-06-05
US48965903P 2003-07-23 2003-07-23
US49339203P 2003-08-07 2003-08-07
PCT/US2003/034655 WO2004099137A1 (en) 2003-05-02 2003-10-31 Aminocyclohexyl ether compounds and uses thereof

Publications (3)

Publication Number Publication Date
BR0318278A true BR0318278A (pt) 2006-05-23
BRPI0318278B1 BRPI0318278B1 (pt) 2018-11-06
BRPI0318278B8 BRPI0318278B8 (pt) 2024-01-09

Family

ID=33437310

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122018009866A BR122018009866B8 (pt) 2003-05-02 2003-10-31 métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
BRPI0318278A BRPI0318278B8 (pt) 2003-05-02 2003-10-31 Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122018009866A BR122018009866B8 (pt) 2003-05-02 2003-10-31 métodos para preparar compostos de éter aminocicloexílico e compostos intermediários

Country Status (21)

Country Link
US (3) US20070099983A1 (pt)
EP (3) EP2298735A1 (pt)
JP (2) JP4919661B2 (pt)
KR (1) KR101059379B1 (pt)
AT (2) ATE529401T1 (pt)
AU (2) AU2003287378B2 (pt)
BR (2) BR122018009866B8 (pt)
CA (1) CA2524323C (pt)
CY (1) CY1105137T1 (pt)
DE (1) DE60305200T2 (pt)
DK (1) DK1560812T3 (pt)
ES (2) ES2264776T3 (pt)
IL (2) IL171653A (pt)
NO (1) NO334094B1 (pt)
NZ (1) NZ543921A (pt)
PL (1) PL227937B1 (pt)
PT (1) PT1560812E (pt)
RU (1) RU2478617C2 (pt)
SG (2) SG167670A1 (pt)
SI (1) SI1560812T1 (pt)
WO (1) WO2004099137A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217918C (zh) * 1998-04-01 2005-09-07 卡迪欧梅制药公司 氨基环己基醚化合物和其用途
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US20070099983A1 (en) * 2003-05-02 2007-05-03 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US20080063707A1 (en) * 2003-05-02 2008-03-13 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
US7345086B2 (en) 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
US7674820B2 (en) 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
US7345087B2 (en) * 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
JP4954864B2 (ja) * 2004-04-01 2012-06-20 カーディオム ファーマ コーポレイション イオンチャネル調節化合物のプロドラッグおよびその使用
WO2005113011A2 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
US7705036B2 (en) * 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
WO2005097087A2 (en) 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
WO2006053037A2 (en) 2004-11-08 2006-05-18 Cardiome Pharma Corp. A new dosing regimen for ion channel modulating compounds for treating acute atrial fibrillation in a human
MX2007005988A (es) 2004-11-18 2007-07-10 Cardiome Pharma Corp Procedimiento sintetico para compuestos de eter aminociclohexilico.
WO2006075778A1 (en) * 2005-01-12 2006-07-20 Astellas Pharma Inc. Production method of optically active cyclohexane ether compounds
BRPI0612138B8 (pt) 2005-06-15 2021-05-25 Cardiome Pharma Corp compostos éter aminocicloexílicos e método para fazer os mesmos
JP4167297B2 (ja) * 2005-08-23 2008-10-15 株式会社カネカ ３−アラルキルオキシピロリジン誘導体の製造法
CA2627502C (en) 2005-10-31 2014-04-01 Toray Fine Chemicals Co., Ltd. Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative
JP5004067B2 (ja) * 2005-10-31 2012-08-22 東レ・ファインケミカル株式会社 ベンジルオキシ含窒素環状化合物の製造法
JP2007131597A (ja) * 2005-11-11 2007-05-31 Toray Fine Chemicals Co Ltd ベンジルオキシピロリジン誘導体の製造方法
JP5004073B2 (ja) * 2006-06-13 2012-08-22 東レ・ファインケミカル株式会社 光学活性ベンジルオキシピロリジン誘導体塩酸塩粉体及びその製造法
WO2008137778A2 (en) * 2007-05-04 2008-11-13 Cardiome Pharma Corp. Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia
EP2605772B1 (en) 2010-08-16 2016-06-22 Cardiome International AG Process for preparing aminocyclohexyl ether compounds
WO2012024104A2 (en) 2010-08-16 2012-02-23 Codexis, Inc. Biocatalysts and methods for the synthesis of (1r,2r)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine
EP3174935B1 (de) * 2014-08-01 2023-06-21 Covestro Intellectual Property GmbH & Co. KG Copolycarbonat-zusammensetzungen mit cyclischen und linearen oligomeren und verbesserten optischen eigenschaften

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2954380A (en) * 1958-11-26 1960-09-27 Us Vitamin Pharm Corp Piperazinocyclohexyl esters
US3218328A (en) * 1963-02-18 1965-11-16 U S Vitamin & Pharmacentical C Heterocyclic amino phenoxyacetic acids, acid addition salts and quaternary ammonium salts thereof
DE2259260A1 (de) 1972-12-04 1974-06-06 Merck Patent Gmbh Neue amine
US4145435A (en) * 1976-11-12 1979-03-20 The Upjohn Company 2-aminocycloaliphatic amide compounds
US4179501A (en) * 1976-11-12 1979-12-18 The Upjohn Company Analgesic N-(2-aminocycloaliphatic)azidobenzamides
DE2658401A1 (de) 1976-12-23 1978-07-06 Merck Patent Gmbh Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US4598087A (en) * 1983-12-06 1986-07-01 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US4656182A (en) 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
SE8502455L (sv) * 1984-05-18 1985-11-19 Glaxo Group Ltd Aminocyklopentyletrar och deras framstellning samt farmaceutisk beredning
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
WO1987002584A1 (en) 1985-10-25 1987-05-07 The Upjohn Company Cis-n-(2-aminocycloaliphatic)benzene acetamide and -benzamide anticonvulsants
US5059620A (en) * 1985-12-27 1991-10-22 The Du Pont Merck Pharmaceutical Company Aryl substituted aminomethyl benzene derivatives
US4855316A (en) * 1988-02-18 1989-08-08 Warner-Lambert Company 1,2-diamino-4,5-dimethoxycyclohexyl amide analgesic compounds
US5051428A (en) * 1988-12-06 1991-09-24 Warner-Lambert Company 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
AU626949B2 (en) 1988-12-06 1992-08-13 Warner-Lambert Company 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
US4906655A (en) * 1989-01-24 1990-03-06 Warner-Lambert Company Novel 1,2-cyclohexylaminoaryl amides useful as analgesic agents
JPH02270864A (ja) 1989-04-12 1990-11-05 Asahi Glass Co Ltd フルオロカルバサイクリックヌクレオシドおよびその製造法
US5428031A (en) * 1991-12-03 1995-06-27 Merck & Co., Inc. Methods of treating cardiac arrhythmia
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
CA2058502A1 (en) 1991-12-27 1993-06-28 David C. Horwell 2-amino-mono-methoxycyclohexyl amides useful as analgesics
EP0552386A1 (en) 1992-01-13 1993-07-28 Warner-Lambert Company 2-Amino-3 or 6-methoxycyclohexyl amide derivatives
US5506257A (en) * 1992-03-26 1996-04-09 University Of British Columbia Aminocyclohexylamides for antiarrhythmic and anaesthetic uses
WO1993019056A1 (en) 1992-03-26 1993-09-30 The University Of British Columbia Aminocyclohexylamides for antiarrhythmic and anaesthetic uses
GB9220286D0 (en) 1992-09-25 1992-11-11 Merck Sharp & Dohme Therapeutic agents
US5451596A (en) 1992-12-29 1995-09-19 Rhone Poulenc Rorer Pharmaceuticals Inc. Cycloalkyl amine bis-aryl squalene synthase inhibitors
US5747278A (en) * 1993-05-21 1998-05-05 California Institute Of Technology DNA encoding inward rectifier, G-protein activated, mammalian, potassium KGA channel and uses thereof
US5492825A (en) * 1993-08-06 1996-02-20 The Regents Of The University Of California Mammalian inward rectifier potassium channel cDNA, IRK1, corresponding vectors, and transformed cells
ATE211135T1 (de) 1993-09-24 2002-01-15 Univ British Columbia Aminocyclohexylester und ihre anwendung
GB9406043D0 (en) * 1994-03-26 1994-05-18 Smithkline Beecham Plc Compounds
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
AU699272B2 (en) * 1994-08-02 1998-11-26 Merck Sharp & Dohme Limited Azetidine, pyrrolidine and piperidine derivatives
US5750537A (en) * 1994-09-19 1998-05-12 Fujisawa Pharmaceutical Co., Ltd. Use of 5HT3 antagonist to treat impotence
US5556990A (en) 1994-12-16 1996-09-17 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polyarylcarbamoylaza- and -carbamoylalkanedioic acids
ES2176429T3 (es) 1995-02-03 2002-12-01 Basf Ag Disociacion de racementos de aminas primarias y secundarias substituidas por hteroatomos mediante acilado catalizado por via enzimatica.
WO1997026862A2 (de) 1996-01-25 1997-07-31 Schering Aktiengesellschaft Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung
US5646151A (en) 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
CA2258850A1 (en) 1996-06-27 1997-12-31 Smithkline Beecham Corporation Il-8 receptor antagonists
US5935945A (en) * 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US6180632B1 (en) * 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6399618B1 (en) 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
TW536401B (en) 1997-09-03 2003-06-11 Cardiome Pharma Corp A pharmaceutical composition of N,N-bis(phenylcarbamoylmethyl)dimethylammomum chloride and derivatives for the treatment of pain
BR9814048A (pt) 1997-09-26 2000-10-03 Nortran Pharmaceuticals Inc "misturas de enantiÈmetros de aminociclohexil amidas para produzir de modo simultâneo analgesia com anestesia local ou antiarritmia "
JP3773644B2 (ja) * 1998-01-06 2006-05-10 芝府エンジニアリング株式会社 接点材料
US6013830A (en) 1998-03-30 2000-01-11 Sepracor Inc. Asymmetric grignard synthesis with cyclic 1,2 aminoalcohols
CN1217918C (zh) * 1998-04-01 2005-09-07 卡迪欧梅制药公司 氨基环己基醚化合物和其用途
US6624761B2 (en) * 1998-12-11 2003-09-23 Realtime Data, Llc Content independent data compression method and system
US6979685B1 (en) * 1999-02-12 2005-12-27 Cardiome Pharma Corp. Cycloalkyl amine compounds and uses thereof
WO2000047547A2 (en) 1999-02-12 2000-08-17 Nortran Pharmaceuticals Inc. Cycloalkyl amine compounds and uses thereof
AU2899400A (en) * 1999-03-04 2000-09-21 Nortran Pharmaceuticals Inc. Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
US7507545B2 (en) * 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
CA2268590A1 (en) * 1999-04-12 2000-10-12 Nortran Pharmaceuticals Inc. Ion channel modulating compounds and uses thereof
US6150357A (en) * 1999-05-10 2000-11-21 Merck & Co., Inc. Potassium channel agonists
MXPA02010261A (es) * 2000-04-20 2003-04-25 Hoffmann La Roche Derivados de pirrolidina y piperidina y su uso para el tratamiento de transtornos neurodegenerativos.
CA2311483A1 (en) 2000-06-12 2001-12-12 Gregory N Beatch IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF
US6521619B2 (en) * 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
US6498170B2 (en) * 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US7057053B2 (en) * 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US20040049049A1 (en) * 2002-06-14 2004-03-11 Johnson Matthey Pharmaceutical Materials, Inc. Stereoselective synthesis of 1,2-disubstituted cycloalkyls
AU2003251937A1 (en) 2002-07-12 2004-02-02 Cardiome Inc. Mutations of voltage-gated potassium channels
WO2004098525A2 (en) 2003-05-02 2004-11-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
US20070099983A1 (en) * 2003-05-02 2007-05-03 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
WO2005016242A2 (en) * 2003-06-04 2005-02-24 Cardiome Pharma Corp. Synthetic process for trans-aminocyclohexyl ether compounds
US7674820B2 (en) * 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
US20070197632A1 (en) * 2003-10-31 2007-08-23 Cardiome Pharma Corp Aminocyclohexyl ether compounds and uses thereof
US7345087B2 (en) * 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof

Also Published As

Publication number Publication date
JP2007077162A (ja) 2007-03-29
SG167670A1 (en) 2011-01-28
KR20060057531A (ko) 2006-05-26
BRPI0318278B1 (pt) 2018-11-06
RU2008104198A (ru) 2009-08-10
EP1666459A2 (en) 2006-06-07
EP2298735A1 (en) 2011-03-23
CA2524323C (en) 2012-05-15
NO20055130D0 (no) 2005-11-02
AU2011201015B2 (en) 2012-02-02
US20110004006A1 (en) 2011-01-06
IL171653A (en) 2013-06-27
NO20055130L (no) 2005-12-01
CA2524323A1 (en) 2004-11-18
US20070099983A1 (en) 2007-05-03
US8163938B2 (en) 2012-04-24
US20070254945A1 (en) 2007-11-01
NO334094B1 (no) 2013-12-09
IL216579A0 (en) 2012-01-31
ATE325789T1 (de) 2006-06-15
HK1091814A1 (zh) 2007-01-26
EP1560812B1 (en) 2006-05-10
JP2006525227A (ja) 2006-11-09
EP1666459A3 (en) 2006-09-20
BR122018009866B8 (pt) 2021-07-27
SI1560812T1 (sl) 2006-10-31
AU2003287378A1 (en) 2004-11-26
AU2003287378B2 (en) 2010-12-16
BR122018009866B1 (pt) 2018-12-18
DE60305200T2 (de) 2007-05-10
AU2011201015A1 (en) 2011-03-31
SG2010079697A (en) 2016-09-29
EP1560812A1 (en) 2005-08-10
NZ543921A (en) 2008-11-28
JP4919661B2 (ja) 2012-04-18
DE60305200D1 (de) 2006-06-14
PT1560812E (pt) 2006-09-29
EP1666459B1 (en) 2011-10-19
DK1560812T3 (da) 2006-09-04
US7767830B2 (en) 2010-08-03
WO2004099137A1 (en) 2004-11-18
ES2375820T3 (es) 2012-03-06
ES2264776T3 (es) 2007-01-16
ATE529401T1 (de) 2011-11-15
IL216579A (en) 2015-02-26
PL378918A1 (pl) 2006-06-12
BRPI0318278B8 (pt) 2024-01-09
CY1105137T1 (el) 2010-03-03
RU2478617C2 (ru) 2013-04-10
PL227937B1 (pl) 2018-01-31
KR101059379B1 (ko) 2011-08-26

Similar Documents

Publication Publication Date Title
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
EP1478322A4 (en) Beta 2'-OR 3'-HALONUCLEOSIDE
DK1200418T3 (da) Nematodicide trifluorbutener
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
ATE253063T1 (de) 5-ht1f-agonisten
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
SE0003476D0 (sv) Compounds
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.
ID25478A (id) Agonis 5-ht1f
BR0214529A (pt) compostos terapêuticos
BRPI0410026A (pt) derivados de 3-amino-croman quinolina
CL2004001461A1 (es) Compuestos derivados de 1,2,3,4-tetrahidropirimidina, composicion farmaceutica y su procedimiento de preparacion, procedimiento de preparacion, utiles para tratar o prevenir la hepatitis c.
MY176850A (en) Aminocyclohexyl ether compounds and uses thereof
WO2000050023A3 (en) Use of tamoxifen and related compounds as CLC3 blockers in the treatment of vascular diseases

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 3A ANUIDADE.

B24D Patent annual fee: restoration after fee payment
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 3A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2607 DE 22/12/2020 POR TER SIDO INDEVIDA. UMA VEZ QUE A RESTAURACAO FOI CUMPRIDA EM 19/11/2020.

B25A Requested transfer of rights approved

Owner name: CORREVIO CANADA CORP. (CA)

B25A Requested transfer of rights approved

Owner name: CORREVIO INTERNATIONAL SARL (CH)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2496 DE 06/11/2018 QUANTO AO PRAZO DE VALIDADE. RETIFICACAO (PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/10/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO )